The inspection, conducted from 10 March to 13 March 2025, concluded with no Form 483 issued.
“The company said that it remains committed to producing quality products, embedding a quality culture across the organization, and continuously investing in systems, processes & training of its employees so that it can maintain the highest standards of quality and compliance for all its markets.” JB Chemicals stated.
JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radio-diagnostics, APIs, and intermediates.
The company's consolidated net profit jumped 21.7% to Rs 162.49 crore on a 14.1% rise in net sales to Rs 963.49 crore in Q3 FY25 over Q3 FY24.
Shares of JB Chemicals & Pharmaceuticals rose 0.88% to end at Rs 1,518 on Thursday, 13 March 2025.